Ovarian conservation at the time of hysterectomy for benign disease
- PMID: 16055568
- DOI: 10.1097/01.AOG.0000167394.38215.56
Ovarian conservation at the time of hysterectomy for benign disease
Abstract
Objective: Prophylactic oophorectomy is often recommended concurrent with hysterectomy for benign disease. The optimal age for this recommendation in women at average risk for ovarian cancer has not been determined.
Methods: Using published age-specific data for absolute and relative risk, both with and without oophorectomy, for ovarian cancer, coronary heart disease, hip fracture, breast cancer, and stroke, a Markov decision analysis model was used to estimate the optimal strategy for maximizing survival for women at average risk of ovarian cancer. For each 5-year age group from 40 to 80 years, 4 strategies were compared: ovarian conservation or oophorectomy, and use of estrogen therapy or nonuse. Outcomes, as proportion of women alive at age 80 years, were measured. Sensitivity analyses were performed, varying both relative and absolute risk estimates across the range of reported values.
Results: Ovarian conservation until age 65 benefits long-term survival for women undergoing hysterectomy for benign disease. Women with oophorectomy before age 55 have 8.58% excess mortality by age 80, and those with oophorectomy before age 59 have 3.92% excess mortality. There is sustained, but decreasing, benefit until the age of 75, when excess mortality for oophorectomy is less than 1%. These results were unchanged following multiple sensitivity analyses and were most sensitive to the risk of coronary heart disease.
Conclusion: Ovarian conservation until at least age 65 benefits long-term survival for women at average risk of ovarian cancer when undergoing hysterectomy for benign disease.
Comment in
-
Dogma, skepsis, and the analytic method: the role of prophylactic oophorectomy at the time of hysterectomy.Obstet Gynecol. 2005 Aug;106(2):214-5. doi: 10.1097/01.AOG.0000173317.49461.52. Obstet Gynecol. 2005. PMID: 16055566 No abstract available.
-
Ovarian conservation at the time of hysterectomy for benign disease.Obstet Gynecol. 2005 Nov;106(5 Pt 1):1106-7; author reply 1107. doi: 10.1097/01.AOG.0000186257.37099.46. Obstet Gynecol. 2005. PMID: 16260535 No abstract available.
-
Ovarian conservation at the time of hysterectomy for benign disease.Obstet Gynecol. 2005 Nov;106(5 Pt 1):1106; author reply 1107. doi: 10.1097/01.AOG.0000186052.78067.5a. Obstet Gynecol. 2005. PMID: 16260536 No abstract available.
-
Ovarian conservation at the time of hysterectomy for benign disease.Obstet Gynecol. 2005 Dec;106(6):1413; author reply 1413. doi: 10.1097/01.AOG.0000190480.45127.67. Obstet Gynecol. 2005. PMID: 16319271 No abstract available.
Similar articles
-
Ovarian conservation at the time of hysterectomy for benign disease.Clin Obstet Gynecol. 2007 Jun;50(2):354-61. doi: 10.1097/GRF.0b013e31804a838d. Clin Obstet Gynecol. 2007. PMID: 17513923 Review.
-
Elective oophorectomy for benign gynecological disorders.Menopause. 2007 May-Jun;14(3 Pt 2):580-5. doi: 10.1097/gme.0b013e31803c56a4. Menopause. 2007. PMID: 17476148 Review.
-
Does retention of the ovaries improve long-term survival after hysterectomy? The validity of the epidemiological evidence.Climacteric. 2006 Jun;9(3):161-3. doi: 10.1080/10420150600616027. Climacteric. 2006. PMID: 16766428
-
Bilateral oophorectomy versus ovarian conservation: effects on long-term women's health.J Minim Invasive Gynecol. 2010 Mar-Apr;17(2):161-6. doi: 10.1016/j.jmig.2009.12.016. J Minim Invasive Gynecol. 2010. PMID: 20226402 Review.
-
Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis.J Clin Oncol. 2004 Mar 15;22(6):1045-54. doi: 10.1200/JCO.2004.06.090. Epub 2004 Feb 23. J Clin Oncol. 2004. PMID: 14981106
Cited by
-
Comparative evaluation of reproductive organ-preserving versus standard radical cystectomy in female: a meta-analysis and systematic review of perioperative, oncological, and functional outcomes.Surg Endosc. 2024 Sep;38(9):5041-5052. doi: 10.1007/s00464-024-11074-5. Epub 2024 Jul 15. Surg Endosc. 2024. PMID: 39009729
-
Assessment of Quality of Life after Hysterectomy using European Quality of Life Five Dimension Scale (EQ5D).J Pharm Bioallied Sci. 2023 Jul;15(Suppl 2):S1056-S1058. doi: 10.4103/jpbs.jpbs_227_23. Epub 2023 Jul 11. J Pharm Bioallied Sci. 2023. PMID: 37694084 Free PMC article.
-
Machine learning combined with radiomics and deep learning features extracted from CT images: a novel AI model to distinguish benign from malignant ovarian tumors.Insights Imaging. 2023 Apr 24;14(1):68. doi: 10.1186/s13244-023-01412-x. Insights Imaging. 2023. PMID: 37093321 Free PMC article.
-
Prevalence, socio-demographic determinants, and self-reported reasons for hysterectomy and choice of hospitalization in India.BMC Womens Health. 2022 Dec 12;22(1):514. doi: 10.1186/s12905-022-02072-7. BMC Womens Health. 2022. PMID: 36503443 Free PMC article.
-
Vasomotor symptoms of menopause, autonomic dysfunction, and cardiovascular disease.Am J Physiol Heart Circ Physiol. 2022 Dec 1;323(6):H1270-H1280. doi: 10.1152/ajpheart.00477.2022. Epub 2022 Nov 11. Am J Physiol Heart Circ Physiol. 2022. PMID: 36367692 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
